{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:20:41Z","timestamp":1770063641340,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The National R"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The purpose of this study was to investigate the differences in CT characteristics and disease spread patterns between <jats:italic>ROS1<\/jats:italic>-rearranged adenocarcinomas and epidermal growth factor receptor (<jats:italic>EGFR<\/jats:italic>)-mutant or anaplastic lymphoma kinase (<jats:italic>ALK<\/jats:italic>)-rearranged adenocarcinomas. Patients with stage IIIb\/IV adenocarcinoma with <jats:italic>ROS1<\/jats:italic> rearrangement, <jats:italic>EGFR<\/jats:italic> mutations, or <jats:italic>ALK<\/jats:italic> rearrangement were retrospectively identified. Two radiologists evaluated CT features and disease spread patterns. A multivariable logistic regression model was applied to determine the clinical and CT characteristics that can discriminate between <jats:italic>ROS1<\/jats:italic>-rearranged and <jats:italic>EGFR<\/jats:italic>-mutant or <jats:italic>ALK<\/jats:italic>-rearranged adenocarcinomas. A cohort of 169 patients was identified (<jats:italic>ROS1<\/jats:italic>\u2009=\u200923, <jats:italic>EGFR<\/jats:italic>\u2009=\u2009120, and <jats:italic>ALK<\/jats:italic>\u2009=\u200926). Compared to <jats:italic>EGFR<\/jats:italic>-mutant adenocarcinomas, <jats:italic>ROS1<\/jats:italic>-rearranged adenocarcinomas were less likely to have air-bronchogram (p\u2009=\u20090.011) and pleural retraction (p\u2009=\u20090.048) and more likely to have pleural effusion (p\u2009=\u20090.025), pericardial metastases (p\u2009&lt;\u20090.001), intrathoracic and extrathoracic nodal metastases (p\u2009=\u20090.047 and 0.023, respectively), and brain metastases (p\u2009=\u20090.017). Following multivariable analysis, age (OR\u2009=\u20091.06; 95% CI: 1.01, 1.12; p\u2009=\u20090.024), pericardial metastases (OR\u2009=\u200910.50; 95% CI: 2.10, 52.60; p\u2009=\u20090.005), and nodal metastases (OR\u2009=\u20098.55; 95% CI: 1.14, 62.52; p\u2009=\u20090.037) were found to be more common in <jats:italic>ROS1<\/jats:italic>-rearranged tumors than in non-<jats:italic>ROS1<\/jats:italic>-rearranged tumors. <jats:italic>ROS1<\/jats:italic>-rearranged adenocarcinomas appeared as solid tumors and were associated with young age, pericardial metastases and advanced nodal metastases relative to tumors with <jats:italic>EGFR<\/jats:italic> mutations or <jats:italic>ALK<\/jats:italic> rearrangement.<\/jats:p>","DOI":"10.1038\/s41598-020-73533-y","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T10:04:13Z","timestamp":1601546653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas"],"prefix":"10.1038","volume":"10","author":[{"given":"Jung Han","family":"Woo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joungho","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"73533_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-2559.2008.03176.x","volume":"54","author":"KM Kerr","year":"2009","unstructured":"Kerr, K. M. Pulmonary adenocarcinomas: Classification and reporting. Histopathology 54, 12\u201327. https:\/\/doi.org\/10.1111\/j.1365-2559.2008.03176.x (2009).","journal-title":"Histopathology"},{"key":"73533_CR2","doi-asserted-by":"crossref","unstructured":"Travis, W. D. Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee. Histopathology54, 3\u201311, http:\/\/doi.org\/10.1111\/j.1365-2559.2008.03179.x (2009).","DOI":"10.1111\/j.1365-2559.2008.03179.x"},{"key":"73533_CR3","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1200\/jco.2009.23.6661","volume":"27","author":"L Horn","year":"2009","unstructured":"Horn, L. & Pao, W. EML4-ALK: Honing in on a new target in non-small-cell lung cancer. J. Clin. Oncol. 27, 4232\u20134235. https:\/\/doi.org\/10.1200\/jco.2009.23.6661 (2009).","journal-title":"J. Clin. Oncol."},{"key":"73533_CR4","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129\u20132139. https:\/\/doi.org\/10.1056\/NEJMoa040938 (2004).","journal-title":"N. Engl. J. Med."},{"key":"73533_CR5","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez, J. G. et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497\u20131500. https:\/\/doi.org\/10.1126\/science.1099314 (2004).","journal-title":"Science"},{"key":"73533_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","volume":"30","author":"K Bergethon","year":"2012","unstructured":"Bergethon, K. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863\u2013870. https:\/\/doi.org\/10.1200\/JCO.2011.35.6345 (2012).","journal-title":"J. Clin. Oncol."},{"key":"73533_CR7","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"AT Shaw","year":"2014","unstructured":"Shaw, A. T. et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 371, 1963\u20131971. https:\/\/doi.org\/10.1056\/NEJMoa1406766 (2014).","journal-title":"N. Engl. J. Med."},{"key":"73533_CR8","unstructured":"National Comprehensive Cancer Network. NCCN practice guidelines in oncology: Non-small cell lung cancer. National Comprehensive Cancer Network website. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. Accessed 23 March 2020."},{"key":"73533_CR9","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/j.cllc.2018.12.021","volume":"20","author":"BD Nam","year":"2019","unstructured":"Nam, B. D. et al. Transthoracic rebiopsy for mutation analysis in lung adenocarcinoma: Outcomes and risk factors for the acquisition of nondiagnostic specimens in 199 patients. Clin. Lung Cancer 20, e309\u2013e316. https:\/\/doi.org\/10.1016\/j.cllc.2018.12.021 (2019).","journal-title":"Clin. Lung Cancer"},{"key":"73533_CR10","doi-asserted-by":"publisher","first-page":"809835","DOI":"10.1155\/2015\/809835","volume":"2015","author":"AP Jekunen","year":"2015","unstructured":"Jekunen, A. P. Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments. J. Oncol. 2015, 809835. https:\/\/doi.org\/10.1155\/2015\/809835 (2015).","journal-title":"J. Oncol."},{"key":"73533_CR11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1148\/radiol.14140848","volume":"275","author":"CM Choi","year":"2015","unstructured":"Choi, C. M., Kim, M. Y., Hwang, H. J., Lee, J. B. & Kim, W. S. Advanced adenocarcinoma of the lung: Comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation. Radiology 275, 272\u2013279. https:\/\/doi.org\/10.1148\/radiol.14140848 (2015).","journal-title":"Radiology"},{"key":"73533_CR12","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1007\/s00330-015-4196-z","volume":"26","author":"SJ Hong","year":"2016","unstructured":"Hong, S. J. et al. Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes. Eur. Radiol. 26, 3660\u20133668. https:\/\/doi.org\/10.1007\/s00330-015-4196-z (2016).","journal-title":"Eur. Radiol."},{"key":"73533_CR13","doi-asserted-by":"publisher","unstructured":"Kim, T. J., Lee, C.-T., Jheon, S. H., Park, J.-S. & Chung, J.-H. Radiologic characteristics of surgically resected non-small cell lung cancer with ALK rearrangement or EGFR mutations. Ann. Thorac. Surg.101, 473\u2013480, http:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.athoracsur.2015.07.062 (2016).","DOI":"10.1016\/j.athoracsur.2015.07.062"},{"key":"73533_CR14","doi-asserted-by":"publisher","first-page":"e1753","DOI":"10.1097\/md.0000000000001753","volume":"94","author":"HJ Yoon","year":"2015","unstructured":"Yoon, H. J. et al. Decoding tumor phenotypes for ALK, ROS1, and RET fusions in lung adenocarcinoma using a radiomics approach. Medicine 94, e1753. https:\/\/doi.org\/10.1097\/md.0000000000001753 (2015).","journal-title":"Medicine"},{"key":"73533_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.lungcan.2015.09.018","volume":"90","author":"AJ Plodkowski","year":"2015","unstructured":"Plodkowski, A. J. et al. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?. Lung Cancer 90, 321\u2013325. https:\/\/doi.org\/10.1016\/j.lungcan.2015.09.018 (2015).","journal-title":"Lung Cancer"},{"key":"73533_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4046\/trd.2016.79.2.58","volume":"79","author":"JY Park","year":"2016","unstructured":"Park, J. Y. & Jang, S. H. Epidemiology of lung cancer in Korea: Recent trends. Tuberculosis Respir. Dis. 79, 58\u201369. https:\/\/doi.org\/10.4046\/trd.2016.79.2.58 (2016).","journal-title":"Tuberculosis Respir. Dis."},{"key":"73533_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/s0167-5877(00)00115-x","volume":"45","author":"M Greiner","year":"2000","unstructured":"Greiner, M., Pfeiffer, D. & Smith, R. D. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prevent. Vet. Med. 45, 23\u201341. https:\/\/doi.org\/10.1016\/s0167-5877(00)00115-x (2000).","journal-title":"Prevent. Vet. Med."},{"key":"73533_CR18","doi-asserted-by":"publisher","unstructured":"Planchard, D. et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol29, iv192\u2013iv237, http:\/\/doi.org\/https:\/\/doi.org\/10.1093\/annonc\/mdy275 (2018).","DOI":"10.1093\/annonc\/mdy275"},{"key":"73533_CR19","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1097\/JTO.0000000000000013","volume":"9","author":"S Ren","year":"2014","unstructured":"Ren, S. et al. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J. Thorac. Oncol. 9, e21\u2013e23. https:\/\/doi.org\/10.1097\/JTO.0000000000000013 (2014).","journal-title":"J. Thorac. Oncol."},{"key":"73533_CR20","doi-asserted-by":"publisher","unstructured":"Sun, J.-M. et al. A dramatic response to crizotinib in a non\u2013small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J. Thorac. Oncol.7, e36\u2013e38, https:\/\/doi.org\/10.1097\/JTO.0b013e318274694e (2012).","DOI":"10.1097\/JTO.0b013e318274694e"},{"key":"73533_CR21","doi-asserted-by":"publisher","unstructured":"Li, W. et al. Combinational analysis of FISH and immunohistochemistry reveals rare genomic events\u00a0in ALK fusion patterns in NSCLC that responds\u00a0to Crizotinib treatment. J. Thorac. Oncol.12, 94\u2013101, https:\/\/doi.org\/10.1016\/j.jtho.2016.08.145 (2017).","DOI":"10.1016\/j.jtho.2016.08.145"},{"key":"73533_CR22","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1097\/pas.0b013e3182233e06","volume":"35","author":"A Yoshida","year":"2011","unstructured":"Yoshida, A. et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am. J. Surg. Pathol. 35, 1226\u20131234. https:\/\/doi.org\/10.1097\/pas.0b013e3182233e06 (2011).","journal-title":"Am. J. Surg. Pathol."},{"key":"73533_CR23","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1136\/jcp.2010.081166","volume":"63","author":"R Jokoji","year":"2010","unstructured":"Jokoji, R. et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J. Clin. Pathol. 63, 1066\u20131070. https:\/\/doi.org\/10.1136\/jcp.2010.081166 (2010).","journal-title":"J. Clin. Pathol."},{"key":"73533_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1148\/radiol.2016151455","volume":"280","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. Radiology 280, 271\u2013280. https:\/\/doi.org\/10.1148\/radiol.2016151455 (2016).","journal-title":"Radiology"},{"key":"73533_CR25","doi-asserted-by":"publisher","unstructured":"Gainor, J. F. et al. Patterns of metastatic spread and mechanisms of resistance to Crizotinib in ROS1-positive non-small-cell lung cancer. JCO Precis. Oncol, 1\u201313, http:\/\/doi.org\/https:\/\/doi.org\/10.1200\/po.17.00063 (2017).","DOI":"10.1200\/po.17.00063"},{"key":"73533_CR26","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1200\/jco.2017.75.5587","volume":"36","author":"Y-L Wu","year":"2018","unstructured":"Wu, Y.-L. et al. Phase II study of Crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J. Clin. Oncol. 36, 1405\u20131411. https:\/\/doi.org\/10.1200\/jco.2017.75.5587 (2018).","journal-title":"J. Clin. Oncol."},{"key":"73533_CR27","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1006448 (2010).","journal-title":"N. Engl. J. Med."},{"key":"73533_CR28","doi-asserted-by":"publisher","unstructured":"Goldstraw, P. et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thorac. Oncol.2, 706\u2013714, http:\/\/doi.org\/https:\/\/doi.org\/10.1097\/JTO.0b013e31812f3c1a (2007).","DOI":"10.1097\/JTO.0b013e31812f3c1a"},{"key":"73533_CR29","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1148\/radiol.2363041310","volume":"236","author":"SS Shim","year":"2005","unstructured":"Shim, S. S. et al. Non-small cell lung cancer: Prospective comparison of integrated FDG PET\/CT and CT alone for preoperative staging. Radiology 236, 1011\u20131019. https:\/\/doi.org\/10.1148\/radiol.2363041310 (2005).","journal-title":"Radiology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73533-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73533-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73533-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T20:02:05Z","timestamp":1670356925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73533-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73533"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73533-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"7 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16251"}}